Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy uniQure N-V stock

Own uniQure N-V stock in just a few minutes.

uniQure N.V is a biotechnology business based in the US. uniQure N-V shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. uniQure N-V employs 332 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in uniQure N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – QURE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

uniQure N-V share price

Use our graph to track the performance of QURE stocks over time.

uniQure N-V shares at a glance

Information last updated 2021-03-10.
52-week range$30.76 - $71.45
50-day moving average $36.47
200-day moving average $39.86
Wall St. target price$70.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.80

Buy uniQure N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy uniQure N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

uniQure N-V financials

Revenue TTM $37.5 million
Gross profit TTM $-84,886,000
Return on assets TTM -19.87%
Return on equity TTM -44.1%
Profit margin 0%
Book value $5.45
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting uniQure N-V shares

There are currently 3.0 million uniQure N-V shares held short by investors – that's known as uniQure N-V's "short interest". This figure is 2.4% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting uniQure N-V shares can be evaluated.

uniQure N-V's "short interest ratio" (SIR)

uniQure N-V's "short interest ratio" (SIR) is the quantity of uniQure N-V shares currently shorted divided by the average quantity of uniQure N-V shares traded daily (recently around 479315.61514196). uniQure N-V's SIR currently stands at 6.34. In other words for every 100,000 uniQure N-V shares traded daily on the market, roughly 6340 shares are currently held short.

However uniQure N-V's short interest can also be evaluated against the total number of uniQure N-V shares, or, against the total number of tradable uniQure N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case uniQure N-V's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 uniQure N-V shares in existence, roughly 70 shares are currently held short) or 0.0679% of the tradable shares (for every 100,000 tradable uniQure N-V shares, roughly 68 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against uniQure N-V.

Find out more about how you can short uniQure N-V stock.

uniQure N-V share dividends

We're not expecting uniQure N-V to pay a dividend over the next 12 months.

uniQure N-V share price volatility

Over the last 12 months, uniQure N-V's shares have ranged in value from as little as $30.76 up to $71.45. A popular way to gauge a stock's volatility is its "beta".

QURE.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while uniQure N-V's is 1.2313. This would suggest that uniQure N-V's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

uniQure N-V overview

uniQure N. V. , a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site